Literature DB >> 25536769

[Grippol, Vaxigrip and influvac vaccines--inductors of innate and adaptive immunity factor genes in human blood cells].

T M Sokolova, A N Shuvalov, V V Poloskov, I M Shapoval, M P Kostinov.   

Abstract

AIM: Study the effect of inactivated influenza vaccines on the activity of innate and adaptive immunity genes (TLR3, TLR4 and B2M), RNA-interference Dicer1-gene, production of cytokines (antiviral IFN type I and II, regulatory IL10, IL17) and pro-inflammatory factors IL1-β, TNFα.
MATERIALS AND METHODS: Gene expression was determined by rRT-PCR with authors' primers in human blood cells treated with various doses of the vaccines. Concentration of cytokines by enzyme immunoassay was measured in cultural fluid using "Vector-best" kits.
RESULTS: The studied vaccines have characteristic effects on genetic level. Grippol vaccine predominately stimulates TLR4 gene, activates TLR3, B2M and Dicer1 genes. Influvac vaccine mostly induces TLR3 gene and to a lesser extent TLR4 gene, does not influence the expression of B2M gene and inhibits Dicer1 gene. Vaxigrip split vaccine--the most potent stimulator of gene activity at low doses. Its main targets are TLR3 and B2M genes. All the inactivated vaccines--inductors of high level of IFNγ, low level of TNFα and do not induce IL17. Grippol additionally stimulates secretion of IL1-β, and Vaxigrip - IFNα. Subunit vaccines Grippol and Influvac that contain purified influenza virus hemagglutinins induce IL10 synthesis in blood cells.
CONCLUSION: Immunogenetic characteristics of the inactivated influenza vaccines administered nowadays are obtained.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25536769

Source DB:  PubMed          Journal:  Zh Mikrobiol Epidemiol Immunobiol        ISSN: 0372-9311


  2 in total

1.  Immunogenicity and safety of a novel seasonal influenza preservative-free vaccine manufactured in Kazakhstan: Results of a randomized, comparative, phase II clinical trial in adults.

Authors:  Gulbanu Sarsenbayeva; Yevgeniy Volgin; Markhabat Kassenov; Timur Issagulov; Nikolay Bogdanov; Abylay Sansyzbay; Marina Stukova; Zhanna Buzitskaya; Ilyas Кulmagambetov; Timur Davlyatshin; Berik Khairullin
Journal:  Hum Vaccin Immunother       Date:  2017-12-12       Impact factor: 3.452

2.  Safety and immunogenicity of trivalent inactivated influenza vaccine in adults 60 years of age and older: a phase II, a randomized, comparative trial in Kazakhstan.

Authors:  Gulbanu Sarsenbayeva; Timur Issagulov; Markhabat Kassenov; Ruslan Abitay; Mukhit Orynbayev; Marina Stukova; Maria Pisareva; Timur Davlyatshin; Kutumbetov Lespek; Berik Khairullin
Journal:  Hum Vaccin Immunother       Date:  2020-02-12       Impact factor: 3.452

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.